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Mycobacterium leprae, the causative agent of leprosy, is an unculturable bacterium with
a considerably reduced genome (3.27 Mb) compared to homologues mycobacteria
from the same ancestry. In 2001, the genome of M. leprae was first described and
subsequently four genotypes (1–4) and 16 subtypes (A–P) were identified providing
means to study global transmission patterns for leprosy. In order to understand the
role of asymptomatic carriers we investigated M. leprae carriage as well as infection
in leprosy patients (n = 60) and healthy household contacts (HHC; n = 250) from
Bangladesh using molecular detection of the bacterial element RLEP in nasal swabs
(NS) and slit skin smears (SSS). In parallel, to study M. leprae genotype distribution
in Bangladesh we explored strain diversity by whole genome sequencing (WGS)
and Sanger sequencing. In the studied cohort in Bangladesh, M. leprae DNA was
detected in 33.3% of NS and 22.2% of SSS of patients with bacillary index of 0
whilst in HHC 18.0% of NS and 12.3% of SSS were positive. The majority of the
M. leprae strains detected in this study belonged to genotype 1D (55%), followed by
1A (31%). Importantly, WGS allowed the identification of a new M. leprae genotype,
designated 1B-Bangladesh (14%), which clustered separately between the 1A and
1B strains. Moreover, we established that the genotype previously designated 1C,
is not an independent subtype but clusters within the 1D genotype. Intraindividual
differences were present between the M. leprae strains obtained including mutations
in hypermutated genes, suggesting mixed colonization/infection or in-host evolution.
In summary, we observed that M. leprae is present in asymptomatic contacts of
leprosy patients fueling the concept that these individuals contribute to the current
intensity of transmission. Our data therefore emphasize the importance of sensitive
and specific tools allowing post-exposure prophylaxis targeted at M. leprae-infected
or -colonized individuals.
Keywords: diagnosis, genotypes, strain subtype, WGS, leprosy, M. leprae, RLEP PCR, transmission
Frontiers in Microbiology | www.frontiersin.org 1 June 2020 | Volume 11 | Article 1220
fmicb-11-01220 June 15, 2020 Time: 11:41 # 2
Tió-Coma et al. M. leprae Genotypes in Bangladesh
INTRODUCTION
Mycobacterium leprae and the more recently discovered
Mycobacterium lepromatosis (Han et al., 2008) are the causative
agents of leprosy in humans as well as animals (Truman et al.,
2011; Sharma et al., 2015; Avanzi et al., 2016; Honap et al., 2018;
Schilling et al., 2019b; Tió-Coma et al., 2019a). Leprosy is a
complex infectious disease often resulting in severe, life-long
disabilities and still poses a serious health threat in low- and
middle income countries (World Health Organization, 2019).
Despite the very limited M. leprae genome variability (Singh
and Cole, 2011), the disease presents with characteristically
different clinico-pathological forms (Ridley and Jopling, 1966)
due to genetically dependent differences in the immune response
to the pathogen, resulting in the WHO classification from
paucibacillary (PB) to multibacillary (MB) leprosy (Kumar et al.,
2017). Notwithstanding the efficacy of multidrug therapy (MDT),
approximately 210,000 new cases are still annually diagnosed and
this incidence rate has been stable over the last decade (World
Health Organization, 2019). Aerosol transmission via respiratory
routes is generally assumed to be the most probable way of
bacterial dissemination (Bratschi et al., 2015; Araujo et al., 2016).
Besides bacterial exposure other risk factors have been shown
to be associated with development of leprosy such as genetic
polymorphisms (Mira et al., 2004; Zhang et al., 2009; Wang et al.,
2015; Sales-Marques et al., 2017), the clinical type of the leprosy
index case within a household, immunosuppression (Moet et al.,
2004), and nutritional factors (Dwivedi et al., 2019).
Mycobacterium leprae is closely related to Mycobacterium
tuberculosis, however, its genome has undergone a reductive
evolution resulting in a genome of only 3.27 Mb compared to the
4.41 Mb of M. tuberculosis’ (Cole et al., 2001). Part of the genes
lost in M. leprae included vital metabolic activity, causing it to
be an obligate intracellular pathogen which cannot be cultured
in axenic media that requires support of a host to survive. This
poses major limitations to obtain sufficient bacterial DNA for
research purposes including whole genome sequencing (WGS).
Nevertheless, in 2001 the genome of M. leprae was first published
(Cole et al., 2001) leading to the classification of M. leprae into
four main genotypes (1–4) (Monot et al., 2005) and subsequently
further allocation into 16 subtypes (A–P) (Monot et al., 2009;
Truman et al., 2011). The genome of M. leprae contains several
repetitive elements such as RLEP which present 37 copies and
has been widely applied in molecular diagnostics to specifically
detect the presence of this mycobacterium (Donoghue et al.,
2001; Truman et al., 2008; Martinez et al., 2011; Braet et al., 2018).
Single-nucleotide polymorphism (SNP) genotyping and WGS
are powerful approaches to investigate pathogen transmission as
well as bacterial dissemination and evolution through genome
characterization (Monot et al., 2005, 2009; Han and Silva, 2014).
The limited variation observed in the M. leprae genome permits
the reconstruction of historic human migration patterns and the
origin of M. leprae (Donoghue, 2019). Over the years, several
studies have contributed to the detection and characterization
of M. leprae genomes originating from patients all around the
world (Monot et al., 2005, 2009; Benjak et al., 2018) as well as
from ancient skeletons (Suzuki et al., 2010; Schuenemann et al.,
2013, 2018; Mendum et al., 2014; Krause-Kyora et al., 2018),
red squirrels (Avanzi et al., 2016; Schilling et al., 2019a; Tió-
Coma et al., 2019a), armadillos (Truman et al., 2011; Sharma
et al., 2015), non-human primates (Honap et al., 2018), and soil
(Lavania et al., 2006, 2008; Turankar et al., 2012, 2014, 2016, 2019;
Tió-Coma et al., 2019b). Moreover, skeleton remains have been
successfully applied to retrospectively assess whether individuals
who contributed to the care of leprosy patients such as the
priest Petrus Donders, had developed leprosy (Van Dissel et al.,
2019). In the last few years, new tools were developed allowing
direct sequencing of M. leprae from various types of clinical
isolates (Avanzi et al., 2016; Benjak et al., 2018; Schuenemann
et al., 2018). However, these methods were never applied on
challenging samples such as slit skin smears (SSS) and nasal swabs
(NS) containing a low amount of bacterial DNA compared to skin
lesions of patients.
Household contacts of leprosy patients are a high risk
group for developing the disease (Richardus et al., 2019), and
might serve as asymptomatic carriers contributing to bacterial
dissemination. PCR and quantitative PCR (qPCR) are reliable
techniques to detect M. leprae DNA and have been proposed as
tools for early diagnosis of leprosy, particularly among household
contacts of newly diagnosed patients (Gama et al., 2018, 2019).
In Brazil, M. leprae DNA has been detected in 15.9–42.4% of
healthy household contacts (HHC) in SSS, 9.7–35.2% in blood
(Gama et al., 2018; Santos et al., 2018) and 8.9–49.0% in NS (Brito
e Cabral et al., 2013; Araujo et al., 2016; Carvalho et al., 2018).
Other studies from India, Indonesia and Colombia reported 21%
of M. leprae positivity in SSS of HHC (Turankar et al., 2014), 7.8%
(van Beers et al., 1994) and 16.0–31.0% in NS (Cardona-Castro
et al., 2008; Romero-Montoya et al., 2017).
Detection of host markers, such as serum IgM levels of anti-
M. leprae phenolic glycolipid I (PGL-I), represents an alternative
approach to diagnose infected individuals (Penna et al., 2016;
van Hooij et al., 2017; Barbieri et al., 2019). However, although
detection of M. leprae DNA as well as antibodies against PGL-I
indicate infection with M. leprae, this does not necessarily result
in disease. Thus, these tests alone are not sufficient to identify
the complete leprosy spectrum (Spencer and Brennan, 2011;
van Hooij et al., 2019).
Bangladesh is a leprosy endemic country reporting up to 3,729
new leprosy cases in 2018 (World Health Organization, 2019).
However, M. leprae whole genomes (n = 4) from Bangladesh,
have only been described in one study (Monot et al., 2009)
in which genotypes 1A, 1C, and 1D were identified. To gain
more insight into M. leprae genome variation and transmission
routes in endemic areas in Bangladesh as well as the potential
role of asymptomatic carriers, we explored the diversity and
transmission of M. leprae in four districts of the northwest of
Bangladesh. We collected SSS and NS of 31 leprosy patients
with a high bacterial load as well as 279 of their household
contacts and characterized M. leprae DNA by WGS or Sanger
sequencing. The resulting genotypes were correlated to the
subjects’ GIS location. Additionally, this is the first study to
examine M. leprae DNA detection in comparison to anti-PGL-I
IgM levels in plasma measured by up-converting phosphor lateral
flow assays (UCP-LFAs).
Frontiers in Microbiology | www.frontiersin.org 2 June 2020 | Volume 11 | Article 1220
fmicb-11-01220 June 15, 2020 Time: 11:41 # 3
Tió-Coma et al. M. leprae Genotypes in Bangladesh
MATERIALS AND METHODS
Study Design and Sample Collection
Newly diagnosed leprosy patients (index case, n = 31)
with bacteriological index (BI) ≥ 2 and 3–15 household
contacts of each index case (n = 279) were recruited between
July 2017 and May 2018 (Supplementary Table S1 and
Supplementary Data S1) in four districts of Bangladesh
(Nilphamari, Rangpur, Panchagar and Thakurgaon).
Patients with five or fewer skin lesions and BI 0 were
grouped as PB leprosy. Patients with more than five
skin lesions were grouped as MB leprosy and BI was
determined. The prevalence in the districts where
this study was performed was 0.9 per 10,000 and the
new case detection rate 1.18 per 10,000 (Rural health
program, the leprosy mission Bangladesh, yearly district
activity report 2018).
For M. leprae detection and characterization, SSS from 2
to 3 sites of the earlobe and NS (tip wrapped with traditional
fiber, CLASSIQSwabs, Copan, Brescia, Italy) were collected and
stored in 1 ml 70% ethanol at −20◦C until further use. For
immunological analysis, plasma was collected (van Hooij et al.,
2017, 2018, 2019).
Subjects included in the study were followed up for
surveillance of new case occurrence for ≥24 months after
sample collection.
DNA Isolation From Slit Skin Smears and
Nasal Swabs
DNA was isolated using DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA) as per manufacturer’s instructions with minor
modifications. Briefly, tubes containing 1 ml 70% ethanol and
SSS were vortexed for 15 s. Slit skin smears were removed and
tubes were centrifuged for 15 min at 14000 rpm. Supernatants
were removed and buffer ATL (200 µl) and proteinase K (20 µl,
Qiagen, provided in the Kit) added. NS were transferred to
new microtubes and the microtubes containing the remaining
ethanol were centrifuged at 14000 rpm for 15 min. Supernatants
were removed and NS were inserted again in the tubes, prior
addition of ATL buffer (400 µl) and proteinase K (20 µl).
Slit skin smears and NS samples were incubated at 56◦C
for 1 h at 1100 rpm. Next, AL buffer (200 µl, Qiagen,
provided in the Kit) was added and incubated at 70 ◦C for
10 min at 1400 rpm. Column extraction was performed after
absolute ethanol precipitation (200 µl) as per manufacturer’s
instructions. To avoid cross contamination tweezers were
cleaned first with hydrogen peroxide and then with ethanol
between samples.
RLEP PCR and qPCR
RLEP PCR (Donoghue et al., 2001) was performed as previously
described (Tió-Coma et al., 2019b). Briefly, the 129 bp RLEP
sequence was amplified in 50 µl by addition of 10 µl 5x
Gotaq R© Flexi buffer (Promega, Madison, WI), 5 µl MgCl2
(25 mM), 2 µl dNTP mix (5 mM), 0.25 µl Gotaq R© G2 Flexi
DNA Polymerase (5 u/µl), 5 µl (2 µM) forward and reverse
primers (Supplementary Table S2) and 5 µl template DNA,
water (negative control) or M. leprae DNA (Br4923 or Thai-53
DNA, BEI Resources, Manassas, VA) as positive control. PCR
mixes were subjected to 2 min at 95◦C followed by 40 cycles
of 30 s at 95◦C, 30 s at 65◦C and 30 s at 72◦C and a final
extension of 10 min at 72◦C. PCR products (15 µl) were used
for electrophoresis in a 3.5% agarose gel at 130 V. Amplified
DNA was visualized by Midori Green Advance staining (Nippon
Genetics Europe, Dueren, Germany) using iBrightTM FL1000
Imaging System (Invitrogen, Carlsbad, CA).
Samples from index cases and a selection of contacts for
sequencing were also evaluated by qPCR (Martinez et al., 2009).
The mix included 12.5 µl TaqMan Universal Master Mix II
(Applied Biosystems, Foster City, CA), 0.5 µl (25 µM) forward
and reverse primers (Supplementary Table S2), 0.5 µl (10 µM)
TaqMan probe (Supplementary Table S2) and 5 µl template
DNA were mixed in a final volume of 25 µl. DNA was amplified
using the following profile: 2 min at 50◦C and 10 min at 95◦C
followed by 40 cycles of 15 s at 95◦C and 1 min at 60◦C
with a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems). Presence of M. leprae DNA was considered if a
sample was positive for RLEP qPCR with a cycle threshold (Ct)
lower than 37.5 or was positive for RLEP PCR at least in two out
of three indecently performed PCRs to avoid false positives.
Library Preparation and Enrichment
A total of 60 DNA extracts were selected for WGS, including
30 from SSS and 30 from NS (Supplementary Figure S1
and Supplementary Data S1). At least one sample from each
index case (MB leprosy patient) was selected as well as RLEP
positive samples of HHC and MB or PB patients who were
household contacts of the index case (selection based on Ct
value and household overlap). For 12 subject both SSS and
NS samples were selected for WGS. A maximum of 1 µg of
DNA in a final volume of 50 µl was mechanically fragmented
to 300 bp using the S220 Focused-ultrasonicator (Covaris)
following the manufacturer’s recommendations and cleaned-
up using a 1.8× ratio of AMPure beads. Up to 1 µg of
fragmented DNA was used to prepare indexed libraries using
the Kapa Hyperprep kit (Roche) and the Kapa dual-indexed
adapter kit as previously described (Benjak et al., 2018) followed
by two rounds of amplification. All libraries were quantified
using the Qubit fluorimeter (Thermo Fisher Scientific, Waltham,
MA), and the fragment size distribution was assessed using a
fragment analyzer.
Libraries were target enriched for the M. leprae genome
using a custom MYbaits Whole Genome Enrichment kit
(ArborBioscence) as previously described (Honap et al., 2018).
Briefly, biotinylated RNA baits were prepared using DNA
from M. leprae Br4923. A total of 1500 ng of each amplified
library was used for enrichment. Each library was pooled
prior to enrichment with another library with similar qPCR
Ct value. Enrichment was conducted according to the MYbaits
protocol with the hybridization being carried out at 65◦C for
24 h. After elution, all pools were amplified using the Kapa
amplification kit with universal P5 and P7 primers (Roche). All
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amplification reactions were cleaned up using the AMPure beads
(1× ratio).
Illumina Sequencing
Pools were multiplexed on one lane of a NextSeq instrument with
a total amount of 20–30 million reads per pool. Some libraries
were deep sequenced based on the mapping statistics obtained
in the first run.
Raw reads were processed and aligned to M. leprae TN
reference genome (GenBank accession number AL450380.1) as
previously described using an in-house pipeline (Benjak et al.,
2018). A minimum depth coverage of 5 was considered for
further phylogenetic analysis.
Sequencing Analysis
Genome comparison was based on analysis of SNPs (analyzed
with VarScan v2.3.9; Koboldt et al., 2012) and Indels (analyzed
with Platypus v0.8.171; Rimmer et al., 2014) as formerly
reported (Benjak et al., 2018). The newly sequenced M. leprae
genomes were aligned with 232 genomes available in public
databases (Schuenemann et al., 2018; Avanzi et al., 2020).
Sites below 80% and above 20% alignment difference were
also reported. A comparison to 259 M. leprae genomes
(including 27 new genomes) allowed the identification of
unique SNPs per index case. Each candidate SNP or Indel
was checked manually on Integrative Genomics Viewer
(Robinson et al., 2011).
Genotyping and Antimicrobial
Resistance by Sanger Sequencing
To further characterize the M. leprae strains for which the
whole genome sequence was not obtained, specific primers
were designed to perform Sanger sequencing based on unique
SNPs (Supplementary Tables S3, S4) of each index case strain.
Additionally, Sanger sequencing was performed after amplifying
several loci (Supplementary Table S2) to subtype the genomes
based on standard the M. leprae classification (Monot et al.,
2009; Truman et al., 2011) and to determine antimicrobial
resistance to rifampicin (rpoB), dapsone (folP1) or ofloxacin
(gyrA). Genotyping by Sanger sequencing was performed to all
RLEP PCR positive samples (including samples obtained from
leprosy patients and HHC) without a whole genome sequence
with a depth coverage of ≥5. PCRs were performed with 5 µl
of template DNA using the aforementioned PCR mixes. DNA
was denatured for 2 min at 95◦C, followed by 45 cycles of
30 s at 95◦C, 30 s at 50–58◦C and 30 s at 72◦C and a
final extension cycle of 10 min at 72◦C. PCR products were
resolved by agarose gel electrophoresis as explained above. PCR
products showing a band were purified prior to sequencing
using the Wizard SV Gel and PCR Clean-Up System (Promega).
Sequencing was performed on the ABI3730xl system (Applied
Biosystems) using the BigDye Terminator Cycle Sequencing
Kit (Thermo Fisher Scientific). Sequences were analyzed using
Bioedit v7.0.5.3.
Anti-PGL-I UCP-LFA
Up-converting phosphor lateral flow assays were performed
using the LUMC developed LFA based on luminescent up-
converting reporter particles for quantitative detection of
anti-M. leprae PGL-I IgM as previously described (van
Hooij et al., 2017, 2018, 2019). Plasma samples (n = 308,
two samples excluded due to labeling mistake) were
thawed and diluted (1:50) in assay buffer. Strips were
placed in microtiter plate wells containing 50 µl diluted
samples and target specific UCP conjugate (PGL-I, 400 ng).
Immunochromatography continued for at least 30 min
until dry. Scanning of the LFA strips was performed by
LFA strip readers adapted for measurement of the UCP
label (UPCON; Labrox, Finland). Results are displayed as
the Ratio (R) value between Test and Flow-Control signal
based on relative fluorescence units (RFUs) measured at the
respective lines. The threshold for positivity for the αPGL-I
UCP-LFA was 0.10.
RESULTS
M. leprae Detection in Patients and
Healthy Household Contacts
At diagnosis of the index cases and recruitment of contacts
in this study out of 279 household contacts 250 presented no
signs or symptoms of leprosy or other diseases (HHC), whereas
22 household contacts were diagnosed as PB and seven as MB
patients (Supplementary Table S1 and Supplementary Data S1)
and therefore were excluded from the HHC group.
Presence of M. leprae DNA was determined by RLEP
PCR or qPCR in SSS and NS of leprosy patients and HHC
(Figure 1 and Supplementary Data S1): as expected in
MB patients with BI 2–6 M. leprae DNA was almost always
detectable in both SSS (96.8%) and NS (90.9%). This was
much lower in PB and MB patients with BI 0 ranging
from 22.2% in SSS to 33.3% in NS. Positivity rates in HHC
were not very different from those observed for PB and
MB patients with BI 0, with 12.3% positive samples in SSS
and 18.0% in NS. Showing a similar M. leprae carriage
between HHC and patients with BI 0. Moreover, the
overall Ct range was lower for SSS [16.3–37.1] compared
to NS [20.1–39.4] showing that SSS contained more
M. leprae DNA and is a preferred sample for its detection
(Supplementary Data S1).
HHC (n = 250) were followed up clinically for ≥24
months after sample collection and four of them developed
leprosy within the first year. RLEP PCR performed on DNA
isolated before disease occurrence showed a positive result
from SSS in one patient (5 months before diagnosis) and
a positive result from NS in another (8 months before
diagnosis). All of the new cases developed PB leprosy with
BI of 0 and three were genetically related to the index
case (parent and child of index case H03 and second
degree relative of index case H30) and one was the spouse
(index case H10).
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FIGURE 1 | Study design, RLEP positivity and genotyped samples. Flow
diagram providing an overview of the subjects recruited for this study. Slit skin
smears (SSS) and nasal swabs (NS) collected per group; healthy household
contacts (HHC), paucibacillary (PB) or multibacillary (MB) patients with BI 0,
and MB patients with a bacteriological index (BI) 2–6. MB patients with BI 1
were not diagnosed within the course of this study. DNA was isolated from
SSS and NS and screened for M. leprae DNA by RLEP PCR. Samples were
genotyped by Sanger sequencing (Monot et al., 2009; Truman et al., 2011) or
Whole Genome Sequencing (Benjak et al., 2018). Percentages of the samples
positive for RLEP PCR and genotyped are shown.
Genome Typing and Antimicrobial
Resistance
Mycobacterium leprae genomes of SSS and NS were genotyped
by WGS or Sanger sequencing. A total of 60 samples (30 SSS
and 30 NS) from MB and PB leprosy patients as well as HHC
were selected for WGS with an RLEP qPCR Ct ranging from
16.2 to 37.2 (Supplementary Data S1). A total of 27 samples
from 21 subjects (21 SSS and 6 NS) passed the library quality
check and were successfully sequenced with a coverage ≥5
(Supplementary Figure S1 and Supplementary Table S5). The
limiting Ct value was 26.2 for SSS and 24.2 for NS.
On applying the genotyping system described by Monot et al.
(2009), Truman et al. (2011), the following genotypes were found
for these 21 subjects: 1A (n = 5), 1B (n = 4), 1C (n = 3), and
1D (n = 9). Interestingly, the four newly sequenced 1B genotype
strains do not cluster with the two previously described 1B strains
from Yemen and Martinique (Figure 2). Instead, they form a
new cluster in the phylogenetic tree located between genotypes
the 1A and 1B, which we refer to as 1B-Bangladesh (Figure 2,
blue and Supplementary Data S1). Using Sanger sequencing, the
M. leprae strain for eight additional individuals were determined
as 1A (n = 4) or 1D (n = 4). Three subjects, including two NS
samples from HHC, carried genotype 1 but subtype could not
be established due to lack of amplification of the subtyping loci
(Supplementary Data S1).
The SNP used to differentiate genotype 1C (A61425G;
Met90Thr, mutated in genotypes 1D and 2–4) is located at
esxA. In contrast to previous observations (Monot et al., 2009;
Truman et al., 2011), we found that this position is not
phylogenetically informative as it is also found unmutated (A;
Met) in strains from the genotype 3I and 2E (Figure 2, green
and Supplementary Data S2). Moreover, the 1C strains clustered
in the middle of the 1D group suggesting that the previously
described genotype 1C is part of the 1D genotype.
Finally, antimicrobial resistance was assessed in all genotyped
strains either by WGS or Sanger sequencing. The latter was
successful on 18 samples for rpoB, five sample for folP1 and 15
samples for gyrA (Supplementary Data S1). None of the strains
with a complete genome harbored drug-resistance mutations.
One NS sample containing a missense mutation in the rpoB
gene (Ser456Thr) in 50% of the sequences potentially leading to
antimicrobial resistance (World Health Organization, 2017) was
identified by Sanger sequencing. Moreover, although not causing
resistance, up to two silent mutations in three different positions
of the rpoB gene relevant for antimicrobial resistance (432, 441,
and 456) were also observed in several subjects.
Distribution and Possible Transmission
of M. leprae Genotypes
The most prevalent M. leprae genotype in the studied area of
Bangladesh is 1D, found in 55% of the individuals (n = 16,
Table 1 and Supplementary Data S1), followed by 1A in
31% (n = 9), and 1B-Bangladesh in 14% (n = 4). Genotype
1D is the most widely distributed throughout the whole area
studied (Figure 3, blue and purple), whilst genotypes 1A and
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FIGURE 2 | Phylogeography of M. leprae strains. Maximum parsimony tree of 259 genomes of M. leprae built in MEGA 7. Support values were obtained by
bootstrapping 500 replicates. Branch lengths are proportional to nucleotide substitutions. The tree is rooted using M. lepromatosis. The strains from Bangladesh are
shown in red and their exact organization in the tree is shown in the two zoomed sections of the genotypes 1A-B and 1D. Strains with an A at SNP61425 in the esxA
gene are shown in green. The specific 1B-Bangladesh genotype/cluster of Bangladesh strains is shown in blue.
the here identified genotype 1B-Bangladesh are only observed
in the eastern area (green and orange, respectively). The latter
genotype was found in four individuals: two from the same
household and two unrelated subjects residing 56, 51, and
11 km from each other. However, due to privacy regulations on
patient information to third parties it could not be established
whether subjects in different households had had contact with
any of the others.
In a total of four households the same M. leprae genotype was
detected in two individuals (Supplementary Data S1). In the first
household, both subjects were MB patients and WGS showed
no genetic variation between both patients’ genomes (RB001
and RB003, 1B-Bangladesh genotype, Supplementary Data S2).
In the second household with two MB patients, the M. leprae
whole genome was only obtained from the index case
but the same genotype, 1A, and a strain-specific SNP of
the index case (Supplementary Tables S3, S4) was also
identified by Sanger sequencing in the other patient (RB182
and RB266). In the last two households, the genotype of
strains from both MB index cases’ were determined by
WGS (RB030, genotype 1D) and, by Sanger sequencing
(RB065, genotype 1D-esxA), while the M. leprae genotype
1 was located in the NS of both HHC but no further
subtyping was possible.
Frontiers in Microbiology | www.frontiersin.org 6 June 2020 | Volume 11 | Article 1220
fmicb-11-01220 June 15, 2020 Time: 11:41 # 7
Tió-Coma et al. M. leprae Genotypes in Bangladesh
TABLE 1 | M. leprae genotypes identified in Bangladesh.
Genotype Number of individual %
1A 9 31.0
1B-Bangladesh 4 13.8
1D 13 44.8
1D-esxA 3 10.4
1* 3
M. leprae genotypes identified in patients and contacts from Bangladesh and
the percentage of each subtype are shown. M. leprae DNA was isolated from
slit skin smears (SSS) and/or nasal swabs (NS). Genotypes were determined by
Whole Genome Sequencing (WGS) or Sanger sequencing according to Monot
et al. (2009), Truman et al. (2011). The new subtype 1B-Bangladesh was
identified by WGS and primers were then designed for use in Sanger sequencing
(Supplementary Table S2). 1D-esxA is 1D subtype containing an A at SNP61425
in the esxA gene, traditionally grouped as 1C (Monot et al., 2009; Truman et al.,
2011). This SNP is also found in strains from the genotype 3I and 2E (Figure 2,
green). 1* are samples with genotype 1 for which the subtype could not be
determined due to DNA concentration limit.
Comparison of M. leprae Genomes From
SSS and NS
Mycobacterium leprae whole genomes of six patients were
successfully recovered from both SSS and NS. The M. leprae
genotypes obtained in each subject were in agreement between
the two samples (Table 2). Genomic comparison showed no
differences between DNA from SSS and NS for two patients:
RB001-RN001 (genotype 1B-Bangladesh) and RB048-RN059
(genotype 1D-esxA, Figure 2 and Supplementary Data S2).
In a third patient (RB073-RN084, genotype 1A), both
strains were identical except that in the NS strain 17%
of 24 reads in ml1512 harbored a T1824441C (Gly56Asp)
(Table 2). Interestingly, ml1512 which encodes a ribonuclease
J is one of the most mutated genes among all M. leprae
strains (Benjak et al., 2018) and mutations at this gene were also
observed in two different patients: in the NS of RN022-RB053
(genotype 1D) 35% of 26 reads had a mutated allele (G1823127A;
Ser494Leu) and 20% of 21 reads had an insertion of a C at
position 1823613 probably leading to a deleterious frameshift; in
the SSS of RB074-RN095 (genotype 1B-Bangladesh) 92% of 92
reads presented a missense mutation (G1823098A; Leu504Phe).
Interestingly, RB074 harbored a G660474C mutation in metK, a
probable methionine adenosyl-transferase, which was also found
in 75% of 12 reads of the NS and is uniquely found in this
subject’s M. leprae genomes. Additionally, RN095 also displayed
mutations at several positions in ml1750 (a putative nucleotide
cyclase): 48% of 21 reads had C2116695A (Pro100Thr), 20% of
20 reads had A2116670G (Gln108Arg) and 19% of 16 reads had
C2116490T mutation (Arg168His). These positions were partially
or totally mutated in other strains from different genotypes: SM1
(100% Pro100Ser; genotype 4), Ml9-81 (Mali, 30% Arg168His;
genotype 4N) and Md05036 (Madagascar, 90% Gln108Arg,
genotype 1D-Mada) (Benjak et al., 2018; Avanzi et al., 2020).
The patient with the M. leprae strains that were the most
genetically different between the NS and SSS carried the genotype
1B-Bangladesh (RB069 and RN165). The NS strain had a mixed
population in glpQ (29% of 76 reads C9231T, Leu34Phe) and
ml1752 (15% of 94 reads C2121552T, Val226Ile). These genes
encode a glycerophosphoryl diester phosphodiesterase, a putative
nucleotide cyclase and a conserved hypothetical protein. Notably,
ml1752 is also one of the most hypermutated genes in M. leprae
(Benjak et al., 2018).
For 11 patients a whole genome sequence was recovered only
from SSS but Sanger sequencing was successfully performed
to identify the subtype in NS. The same subtype observed in
SSS was also found in the NS of these 11 patients. Moreover,
unique M. leprae SNPs identified in the genomes of the SSS
(Supplementary Tables S3, S4) were also detected in seven of the
genomes of the NS of these patients (Supplementary Data S1).
Combining Host and Pathogen Detection
Anti-PGL-I IgM levels were determined in plasma of 308
subjects. All MB patients with BI 2-6 (n = 33) showed high levels
for anti-PGL-I IgM (Table 3) in line with the general consensus
(Geluk et al., 2011; van Hooij et al., 2017). Out of the patients
(both MB and PB) with BI 0 (n = 27), nine (33.3%) were positive
for anti-PGL-I IgM. Similarly, 36.8% of HHC showed positivity
(n = 92). From these 92 positive individuals, 70 were neither
positive for SSS nor NS RLEP PCR (Supplementary Data S1).
Of the four contacts who developed leprosy within the first
year after sample collection, two were positive for anti-PGL-I
IgM whilst negative for RLEP PCRs 10 and 12 months before
diagnosis. Since the two other subjects had a positive RLEP
PCR in SSS or NS 5 or 8 months before diagnosis, it can be
concluded that all of the new cases showed positivity either
for host- or pathogen-associated diagnostics 5-12 months before
developing disease.
Individual anti-PGL-I levels were compared to RLEP Ct values
in SSS and NS samples (Figure 4), showing an expected negative
correlation between anti-PGL-I ratio and Ct value since both
values are associated with BI. A subtle difference can be observed
in the correlation between anti-PGL-I IgM levels and RLEP Ct
if the qPCR was performed on either SSS or NS DNA, with a
coefficient of determination (R2) 0.73 and 0.69, respectively.
DISCUSSION
In this study we investigated M. leprae transmission patterns in
Bangladesh by detecting and sequencing M. leprae DNA derived
from SSS and NS of patients and their household members.
Our data represents the first report of M. leprae DNA detection
in HHC from Bangladesh. We observed moderate positivity in
HHC which was similar to positivity of leprosy patients with
BI 0. A new genotype, 1B-Bangladesh, was sequenced and we
showed that the previously described 1C genotype is part of the
1D group. Additionally, a negative correlation between RLEP Ct
values indicating the amount of M. leprae DNA and anti-PGL-I
IgM levels was observed.
Mycobacterium leprae DNA detection frequency in HHC from
Bangladesh (12.3% in SSS and 18.0% in NS) was in line with
previous studies conducted in several hyperendemic areas of
Brazil, Colombia and Indonesia (van Beers et al., 1994; Cardona-
Castro et al., 2008; Brito e Cabral et al., 2013; Romero-Montoya
et al., 2017; Carvalho et al., 2018; Gama et al., 2018). In India
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FIGURE 3 | Distribution of M. leprae genotypes in Bangladesh. Map of Bangladesh including markers indicating the residence of every subject with at least one
sample genotyped for M. leprae (A), and zoomed into the area of interest (B). Each marker indicates an individual for whom M. leprae genotype was determined,
either from slit skin smear, nasal swab or both samples. Genotype 1A is shown in green, 1B-Bangladesh in orange, 1D in blue, 1D-esxA in purple and 1* in white.
1D-esxA is 1D subtype containing an A at SNP61425 in the esxA gene, formerly grouped as 1C (Monot et al., 2009; Truman et al., 2011). 1* are samples with
genotype 1 for which the subtype could not be determined. The figure was drawn in R (v3.4.3) with the package leaflet (v2.0.2) using maps from Esri – National
Geographic with permission. Scale Not Given. “National Geographic World Map.” December 13, 2011.
http://www.arcgis.com/home/item.html?id=b9b1b422198944fbbd5250b3241691b6 (September 2, 2019).
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TABLE 3 | Anti-PGL-I IgM positivity.
Genotype Number of positive
individual
% of positivity
MB patients BI 2-6 (n = 33) 33 100.0
Patients BI 0 (n = 27) 9 33.3
Healthy household
contacts (n = 250)
9 36.8
Anti-PGL-I antibody levels were measured by up-converting phosphor lateral flow
assay specific for M. leprae PGL-I IgM antibodies (UCP-LFA) using the Ratio
(R) of the Test (T) and flow control (FC) lines as units. Ratios of ≥0.10 were
considered positive.
higher positivity (21.0%) in SSS of HHC was reported (Turankar
et al., 2014) whereas in two Brazilian studies from Uberlandia, up
to 42.4% positivity in SSS (Santos et al., 2018) and 49.0% in NS
(Araujo et al., 2016) were observed. Three factors may limit the
translation of these high positive results from India and Brazil
to our study: (i) the sample sizes of the Indian (Turankar et al.,
2014) and one of the Brazilian studies (Araujo et al., 2016) were
smaller (n = 28 and n = 104, respectively vs. n = 250 HHC in this
study); (ii) we conducted a more stringent approach by testing the
samples in three independent PCRs; and (iii) the epidemiology
and incidence of MB cases in India and Brazil differ from the
studied area in Bangladesh where MB leprosy cases occur less
frequently than PB and also usually display a low BI (Richardus
et al., 2017; van Hooij et al., 2019).
Mycobacterium leprae DNA in the nose does not indicate
disease but (transient) colonization whilst presence of M. leprae
in SSS indicates infection. Thus, the higher RLEP PCR positivity
in NS compared to SSS in patients with BI 0 and HHC likely
represents the (virtual) absence of bacteria causing infection in
these individuals despite colonization.
A longitudinal study conducted in Brazil (Manta et al., 2019),
investigated SSS from 995 HHC by qPCR including follow-
up for at least 3 years with occurrence of five new cases. The
authors reported 20% qPCR positivity in HHC representing
future new cases compared to 9% in HHC without disease.
However, this difference was not significant. In line with that
study, we found that M. leprae DNA detection was slightly higher
(25% vs. 18% in NS and 25% vs. 12% in SSS) in contacts who
developed disease compared to those who did not. Additionally,
we determined anti-PGL-I IgM levels, which correlated well
with Ct qPCR values. Notwithstanding this correlation, serology
provided added value: when positivity in any of the three
techniques was considered (NS PCR, SSS PCR, or anti PGL-I),
all of the contacts (n = 4) who developed leprosy within the
first year after sample collection, were identified. In agreement
with this, a combination of host and pathogen markers was
previously integrated in a machine learning model using qPCR
and serological data (antibodies against LID-1 or ND-O-LID)
(Gama et al., 2019) to identify prospective leprosy patients
among contacts leading to an increased sensitivity in diagnosis,
particularly in PB leprosy. It is of note that in our study, three of
the four contacts who developed leprosy were genetically related
to the index cases in their households, stressing the previously
described role of genetic inheritance in the development of
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FIGURE 4 | Correlation of IgM antibodies against PGL-I to Ct of RLEP qPCR. Quantified levels of pathogen DNA (qPCR) and host immunity were correlated for
samples selected for qPCR analysis based on RLEP positivity in multiple individuals in one household. Each dot represents a sample from one individual; leprosy
patients are indicated in black, and healthy household contact in blue. Anti-PGL-I antibody levels were measured by up-converting reporter particles lateral flow
assay specific for M. leprae PGL-I IgM antibodies (αPGL-I UCP-LFA) using the Ratio (R) of the Test (T) and flow control (FC) lines as units. Ratios of ≥0.10 were
considered positive as indicated by the red dashed line. RLEP cycle threshold (Ct) values are indicated on the x-axis and were measured by qPCR to detect
M. leprae DNA in slit skin smears (SSS, left) and nasal swabs (NS, right). Undetermined Cts are depicted as Ct 40.
leprosy (Mira et al., 2004; Zhang et al., 2009; Wang et al., 2015;
Sales-Marques et al., 2017; Uaska Sartori et al., 2020). For this
reason, the association between leprosy and the genetics of this
Bangladeshi population is currently being studied.
Genotype 1 was identified in all the M. leprae genomes
retrieved from Bangladesh, consistent with previous data from
Monot et al. (2009). In Bangladesh, leprosy was likely introduced
through the southern Asian route (genotype 1) leading to the
spread of M. leprae into the Indian subcontinent, Indonesia and
the Philippines (Monot et al., 2009; Benjak et al., 2018). Subtype
1D was predominantly present in Bangladesh but in addition
we detected 1A and identified a new 1B-Bangladesh genotype.
The presence of multiple subtypes of M. leprae genotype 1
in Bangladesh is in line with previous studies in South Asian
countries such as India, Nepal, Thailand, Indonesia and Pakistan
(Monot et al., 2009; Benjak et al., 2018). The new 1B-Bangladesh
genotype is thus far restricted to Bangladesh and two of the four
individuals carrying this strain were part of the same household
whilst the other two did not have any relationship with each
other and were located in different areas with a distance of
up to 56 km between them. This suggests that this genotype
could be a common subtype in Bangladesh although additional
studies are required to confirm this. Thus, it is of interest
to include the 1B-Bangladesh SNP specific primers in future
epidemiological studies, particularly in other (neighboring) Asian
countries such as India where genotype 1 is widely established
(Monot et al., 2009).
In contrast to the general belief (Monot et al., 2009; Truman
et al., 2011), we observed that subtype 1C does not form
an independent subtype but actually belongs to subtype 1D.
SNP61425 used to distinguish genotypes 1A–C is located at
esxA encoding the virulence factor ESAT-6 (Monot et al., 2009).
The Esx protein family also revealed high diversity in the more
pathogenic mycobacterium,M. tuberculosis (Uplekar et al., 2011),
and is involved in host-pathogen interaction. Of note is that
ESAT-6 (ML0049) is a potent T-cell antigen (Geluk et al., 2002,
2004), thus mutations in esxA gene might indicate drift due
to immune pressure potentially explaining the occurrence of
mutations at SNP61425 in different genotypes.
In a recent survey in 19 countries during 2009–2015 (Cambau
et al., 2018), 8% of the cases presented mutations resulting in
antimicrobial resistance and resistance to up to two different
drugs was detected. In our study, which is the first investigating
M. leprae drug resistance in Bangladesh, we detected no
resistance by WGS, however, a partial missense mutation in
the codon for Ser456 of the rpoB gene potentially leading to
rifampicin resistance (n = 1) was observed by Sanger sequencing.
This could be the result of a mixed infection or an emerging
mutation of the M. leprae strain occurring in the patient.
Silent mutations in the rpoB gene were detected in several
locations, which indicates that mutations do occur, and this may
eventually lead to missense mutations conferring antimicrobial
resistance. However, drug resistance is not only induced by
genetic mutations in drug targets, efflux systems resulting in
antimicrobial resistance have also been described for M. leprae
(Machado et al., 2018). This mechanism of drug resistance is
unnoticed in genomic tests and needs to be further investigated
for leprosy especially in the light of the huge efforts recently
initiated and WHO-endorsed for post-exposure prophylaxis
(PEP) using antibiotic regimens (Barth-Jaeggi et al., 2016; Mieras
et al., 2018; Richardus et al., 2019).
Despite our finding that NS samples were more frequently
positive for M. leprae DNA, recovery of M. leprae whole genomes
from SSS has proven to be more successful than from NS. This is
due to the higher number of bacteria in SSS of patients. However,
the importance of genotyping NS as well as skin biopsies or SSS
to better understand transmission has been previously discussed
(Fontes et al., 2017), as the nasal respiratory route remains one
of the most plausible modes of infection (Bratschi et al., 2015;
Araujo et al., 2016). In a recent study, skin biopsies and NS
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of patients were compared by VNTR typing and the authors
found that out of 38 patients, differences between SSS and NS
in seven loci were observed in 33 patients (Lima et al., 2016).
Although theM. leprae genomes from SSS and NS analyzed in our
study were almost identical, we observed that genomes obtained
from NS harbored more mutations, especially in previously
reported (Benjak et al., 2018) hypermutated genes. This could
be an indication of in-host evolution in the nasal mucosa,
mixed infection or mixed colonization. Thus, it may imply that
colonization occurred with two different strains causing a co-
infection or that one is present, likely from a later colonization,
but does not cause the disease.
The presence of mixed infections emphasizes once more
the importance of monitoring asymptomatic carriers, who may
contribute to the spread of the pathogen. Therefore, providing
PEP only to the (close) contacts of leprosy patients might not be
sufficient to stop transmission. Instead, an approach including
the entire community but targeting only individuals testing
positive for M. leprae DNA or host immune markers associated to
M. leprae infection, would represent a preferred strategy for PEP.
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